| scholarly article | Q13442814 |
| P50 | author | Amalia Gastaldelli | Q43294287 |
| Ralph A. DeFronzo | Q58689309 | ||
| Eleuterio Ferrannini | Q59193801 | ||
| P2093 | author name string | Emma Buzzigoli | |
| Rachele Berria | |||
| Yoshinori Miyazaki | |||
| Archana Mahankali | |||
| Maura Pettiti | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2275-2281 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | The effect of pioglitazone on the liver: role of adiponectin. | |
| P478 | volume | 29 |
| Q46473134 | A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes |
| Q43290066 | A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy |
| Q45365444 | Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q36109894 | Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population |
| Q37240102 | Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes |
| Q28288604 | Expansion of the homeostasis model assessment of β-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2 |
| Q43055288 | Fat mass largely contributes to insulin mediated glucose uptake in morbidly obese subjects |
| Q39653333 | Identification of subgroups with differential treatment effects for longitudinal and multiresponse variables |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q43294210 | Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis |
| Q37577126 | In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion |
| Q30453231 | Inflammation in nonalcoholic steatohepatitis |
| Q33880303 | Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 |
| Q40683672 | Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease |
| Q37686121 | Mechanisms by which the thiazolidinedione troglitazone protects against sucrose-induced hepatic fat accumulation and hyperinsulinaemia |
| Q46314621 | PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules. |
| Q91620551 | Participation of white adipose tissue dysfunction on circulating HDL cholesterol and HDL particle size in apparently healthy humans |
| Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q39413300 | Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum |
| Q37194756 | Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. |
| Q34139048 | Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment |
| Q34781949 | Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials |
| Q36842541 | Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content |
| Q35691510 | Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study |
| Q88316703 | Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis |
| Q27307174 | Pioglitazone increases whole body insulin sensitivity in obese, insulin-resistant rhesus monkeys |
| Q38725752 | Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes |
| Q39938622 | Plasma C5 glucose-to-2H2O ratio does not provide an accurate assessment of gluconeogenesis during hyperinsulinemic-euglycemic clamps in either nondiabetic or diabetic humans |
| Q50988205 | Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. |
| Q35683960 | Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes |
| Q38751451 | Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. |
| Q37065234 | Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetes |
| Q45691213 | Targeting Sirt1 in a rat model of high-fat diet-induced non-alcoholic fatty liver disease: Comparison of Gegen Qinlian decoction and resveratrol |
| Q51311315 | The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo. |
| Q26851905 | Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention |
| Q51485541 | Thiazolidinediones improve beta-cell function in type 2 diabetic patients. |
| Q54468632 | Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. |
Search more.